GK Q&A, page-48

Sorry to be cynical but I wonder what chance any of these drugs really have to get to market in the next few years.
Would it not be easier and more profitable for a company like Pfizer which has a market cap around 2000 times the size of NRT to just buy out NRT and mothball NRTs drug pipeline for a number of years and in the interim just market Pfizers own line of drugs which cost a patient around $60,000 to 100,000 for treatment to get about a 6 month longer life span.